glp-1/gip dual agonist lilly orforglipron oral GLP-1 phase 3 weight loss trial Triple Agonism Based Therapies for

Patients can start treatment within days and adjust their dose based on tolerance and weight loss goals without facing escalating costs

Ninety-eight patients with obesity and MASLD (defined as 10% liver fat by MRI-PDFF) were contained in this substudy

While GLP-1R agonists have demonstrated cardiovascular benefits in clinical trials, including reduced rates of major adverse cardiovascular events (MACE) in T2DM patients, their antithrombotic efficacy is generally considered less potent than that of traditional antithrombotic agents

Biotin helps support healthy hair and skin

Diabetes Obes Metabolism

cDNA was synthesized using SuperScript III reverse transcriptase and oligo(dT) 1218 primer